Affiliation:
1. Reparto di Urologia, Ospedale Generale di Bolzano, Bolzano - Italy
2. Reparto di Patologia, Ospedale Generale di Bolzano, Bolzano - Italy
Abstract
In recent years, we have witnessed the propagation and marketing of numerous diagnostic tests capable of detecting, in the urine of patients, the presence of urothelial tumor markers. None of the different markers studied to date, no one has been able to meet all the requirements of the ideal marker. We present and discuss below the results reported in the literature of two tests approved by the Food and Drug Administration [ImmunoCyt/uCyt+ and Fluorescence In Situ Hybridisation (FISH)], which have been commercially available for about 10 years.